Lantern Pharma (NASDAQ:LTRN) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Lantern Pharma (NASDAQ:LTRN) posted its quarterly earnings results on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.09, FiscalAI reports.

Here are the key takeaways from Lantern Pharma’s conference call:

• Management highlighted a planned FDA Type C meeting for LP-300 (mid-May 2026) proposing protocol amendments to focus on EGFR exon 21 L858R patients, extend treatment cycles to eight, and convert to a single-arm Simon two-stage design to address changing standards of care.
• LP-184 reported encouraging Phase I data (63 patients) with a 48% clinical benefit rate at therapeutic doses, an established RP2D, biomarker-linked activity in DNA damage repair mutations, and planned precision trials in TNBC, NSCLC (KEAP1/STK11), and bladder cancer.
• Wholly-owned subsidiary Starlight/STAR-001 received IND clearance for pediatric CNS trials plus multiple Rare Pediatric Disease and Orphan Drug designations, creating potential for several FDA Priority Review Vouchers as non-dilutive value drivers.
• Lantern is commercializing its RADR/agentic AI product withZeta (AI Center of Excellence in India, 25+ beta partners, multi-tier subscription model) which management says could be a material long-term revenue stream but remains early and unproven.
• Financially, the company had ~$10.1M in cash as of 12/31/25 and expects runway only to roughly late July–mid‑September 2026, stating it will need to raise substantial additional funding in the near term.

Lantern Pharma Price Performance

NASDAQ:LTRN traded up $0.12 during mid-day trading on Monday, reaching $1.24. 3,433,002 shares of the company’s stock traded hands, compared to its average volume of 229,694. The company has a 50 day moving average price of $2.74 and a 200-day moving average price of $3.39. The firm has a market capitalization of $13.81 million, a price-to-earnings ratio of -0.71 and a beta of 1.53. Lantern Pharma has a 12-month low of $1.11 and a 12-month high of $5.74.

Institutional Investors Weigh In On Lantern Pharma

A number of large investors have recently made changes to their positions in the business. Cetera Investment Advisers purchased a new position in shares of Lantern Pharma during the fourth quarter valued at approximately $37,000. XTX Topco Ltd purchased a new stake in Lantern Pharma in the second quarter worth $40,000. CIBC Private Wealth Group LLC bought a new stake in Lantern Pharma in the fourth quarter valued at $47,000. Two Sigma Investments LP bought a new stake in Lantern Pharma in the third quarter valued at $70,000. Finally, Susquehanna International Group LLP purchased a new position in Lantern Pharma during the 3rd quarter valued at $170,000. 28.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Lantern Pharma in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $25.00.

About Lantern Pharma

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.